• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- NEWS BRIEFS September 16, 2026

Lance

MPH, CSP & CIT Retired, CHMM Emeritus

Study suggests carbapenem-resistant Acinetobacter may spread through the air​

News brief

8 minutes ago.
Chris Dall, MA
Topics

Healthcare-Associated Infections

Antimicrobial Stewardship

A new study by Chinese researchers suggests a highly resistant, healthcare-associated bacterial pathogen could be transmitted through the air.

In the study, published yesterday in the American Journal of Infection Control, researchers from Sichuan University investigated the extent of air contamination with carbapenem-resistant Acinetobacter baumannii (CRAB) in an intensive care unit (ICU) at West China Hospital. CRAB is a multidrug-resistant pathogen that tends to infect severely ill hospital patients, and is known to spread in ICUs through contact with contaminated high-touch surfaces and shared medical devices.

The study authors note that while CRAB air contamination has been detected in previous studies or infected or colonized patients, airborne transmission has not been documented.

A challenge for infection prevention and control​

On February 26, 2025, the researchers collected air samples from five rooms in the ICU that had at least one patient who had CRAB recovered from a clinical specimen or screening swab, along with nasal or rectal swabs. Whole-genome sequencing (WGS) was used to analyze CRAB colonies recovered from 13 of 88 (10%) of air samples and nine swab samples. All the CRAB colonies from air samples were collected from multipatient rooms

WGS revealed two sequence types (STs) of CRAB among air and patient samples: ST2, a well-known high-risk lineage, and ST164, an emerging high-risk lineage. Further analysis showed four of nine ST2 isolates were associated with transmission within rooms or between rooms, while all of the ST164 isolates belonged to a common clone and were found in two rooms.

The researchers suggest that daily activities conducted for ICU patients—including mechanical ventilation, endotracheal suctioning, diaper changing, and bed making—could facilitate the air dispersal of CRAB. While multicenter studies are needed to demonstrate that air transmission is a common problem, they say air contamination poses serious challenges for infection prevention and control.

"The route through the air may represent a yet-to-be-recognized, important mode of CRAB spread in ICUs. Without addressing such a route, infection control of CRAB transmission in healthcare settings could be compromised in effectiveness and even fail," they wrote.

​

Vaccine Integrity Project turns its eye to meningococcal and pneumococcal vaccines​

News brief

Today at 1:51 p.m.
Stephanie Soucheray, MA
Topics

Vaccine Integrity Project
Today, the Vaccine Integrity Project (VIP), based at the University of Minnesota’s Center for Infectious Disease Research and Policy (CIDRAP), announced it will examine existing scientific evidence on meningococcal and pneumococcal vaccines for children and young adults for its next independent review. CIDRAP publishes CIDRAP News.

The federal vaccine review and recommendation process is not functioning as it historically has
“Parents and clinicians need to trust that vaccine recommendations are grounded in a comprehensive and transparent review of the best available science,” said VIP Executive Director Michael Osterholm, PhD, MPH. “That need is especially important today, when the federal vaccine review and recommendation process is not functioning as it historically has.”

This is the latest in a series of independent evidence reviews, including reviews of influenza, COVID-19, and respiratory syncytial virus (RSV) immunizations, the hepatitis B birth dose, human papillomavirus (HPV) vaccination, and tetanus, diphtheria, and pertussis (Tdap) vaccination during pregnancy.

All licensed meningococcal and pneumococcal vaccines in the United States, including those protecting against serogroups A, C, W, and Y (MenACWY); serogroup B (MenB); and newer pentavalent vaccines protecting against five vaccine-preventable serogroups (MenABCWY), will be analyzed.

Meningococcal vaccine guidance changed under Kennedy​

Cases of meningococcal disease, a bacterial infection caused by Neisseria meningitidis, are rare in the United States, but there has been an uptick in infections since 2021, driven largely by serogroup Y, which is vaccine-preventable.

Ten percent to 15% of meningococcal infections are fatal, and 10% to 20% of survivors have permanent aftereffects, including brain injury, limb amputation, or hearing loss, according to the Centers for Disease Control and Prevention.

Under new federal vaccine guidelines ushered in this year by Health and Human Services Secretary Robert F. Kennedy Jr., the pneumococcal vaccine is recommended for all children, but the MenB and MenACWY vaccines have been reclassified as recommended only for certain high-risk groups or populations, and other meningococcal vaccines have been relegated to immunization based on “shared clinical decision-making.”

The American Academy of Pediatrics, however, still recommends the vaccines for all children and adolescents.
ALL BRIEFS
 
Back
Top Bottom